Are you Dr. Monga?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
20 Medical Park
Suite 202
Wheeling, WV 26003Phone+1 304-243-6442Fax+1 304-243-3715
Summary
- Dr. Manish Monga, MD is an oncologist in Wheeling, West Virginia. He is currently licensed to practice medicine in West Virginia and Ohio. He is an Assistant Professor at West Virginia University SOM.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
- Cook County Health and Hospitals SystemResidency, Internal Medicine, 1996 - 1999
- Maulana Azad Medical CollegeClass of 1994
Certifications & Licensure
- WV State Medical License 2002 - 2019
- OH State Medical License 2007 - 2012
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 71 citationsEfficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart
The Lancet. Oncology. 2022-02-01 - 60 citationsCheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L. Gillison, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
The Oncologist. 2018-09-01 - 378 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy
The Lancet. Oncology. 2017-12-01
Professional Memberships
- Member